Effect of Prostaglandin Analogues on Central Corneal Thickness: 3-Year Follow-up Results
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the effects of each subgroup of prostaglandin analogues (PGAs) on central corneal thickness (CCT) inpatients with normal tension glaucoma (NTG). Methods: We retrospectively reviewed 55 eyes of 55 patients with NTG who were receiving PGA therapy. Patients who weretreated with 0.005% latanoprost (16 eyes), 0.0015% tafluprost (16 eyes), or 0.004% travoprost (23 eyes) monotherapy wereincluded. CCT assessments were performed at baseline and 1, 2, and 3 years after initiation of treatment. Results: In the NTG group, the mean CCT showed a decreasing trend, and there was a significant difference in mean CCT at 1,2, and 3 years compared with baseline (baseline, 538.16 ± 32.14; 1 year, 526.55 ± 37.30 μm [p = 0.00]; 2 years, 521.67 ± 36.79μm [p = 0.00]; 3 years, 520.43 ± 36.88 μm [p = 0.00]). The reduction of CCT was confirmed by subgroup analysis. In the 0.005%latanoprost group, mean CCT was decreased at 1 year (p = 0.11), 2 years (p = 0.00), and 3 years (p = 0.02). In the 0.0015% tafluprostgroup and the 0.004% travoprost group, mean CCT was also significantly decreased at all years (p = 0.00). No statisticaldifference was observed between the NTG subgroups (p = 0.06). Conclusions: Topical therapy with PGAs appeared to cause a significant decrease in CCT reduction in patients with NTG. Along-term follow-up study including more participants is needed.
Abstract
Purpose: To evaluate the effects of each subgroup of prostaglandin analogues (PGAs) on central corneal thickness (CCT) inpatients with normal tension glaucoma (NTG). Methods: We retrospectively reviewed 55 eyes of 55 patients with NTG who were receiving PGA therapy. Patients who weretreated with 0.005% latanoprost (16 eyes), 0.0015% tafluprost (16 eyes), or 0.004% travoprost (23 eyes) monotherapy wereincluded. CCT assessments were performed at baseline and 1, 2, and 3 years after initiation of treatment. Results: In the NTG group, the mean CCT showed a decreasing trend, and there was a significant difference in mean CCT at 1,2, and 3 years compared with baseline (baseline, 538.16 ± 32.14; 1 year, 526.55 ± 37.30 μm [p = 0.00]; 2 years, 521.67 ± 36.79μm [p = 0.00]; 3 years, 520.43 ± 36.88 μm [p = 0.00]). The reduction of CCT was confirmed by subgroup analysis. In the 0.005%latanoprost group, mean CCT was decreased at 1 year (p = 0.11), 2 years (p = 0.00), and 3 years (p = 0.02). In the 0.0015% tafluprostgroup and the 0.004% travoprost group, mean CCT was also significantly decreased at all years (p = 0.00). No statisticaldifference was observed between the NTG subgroups (p = 0.06). Conclusions: Topical therapy with PGAs appeared to cause a significant decrease in CCT reduction in patients with NTG. Along-term follow-up study including more participants is needed.
참고문헌 (31)
- Coleman AL, "Glaucoma", Lancet, 354, pp.1803~1810 (1999)
- Quigley HA, "Number of people with glaucoma worldwide", Br J Ophthalmol, 80, pp.389~393 (1996)
- Shah R, "Glaucoma", BMJ Clin Evid, 2011, pp.0703~ (2011)
- Kim CS, "Prevalence of primary open-angle glaucoma in central South Korea the Namil study", Ophthalmology, 118, pp.1024~1030 (2011)
- You JY, "Effect of latanoprost on central corneal thickness in unilateral normal-tension glaucoma", J Ocul Pharmacol Ther, 29, pp.335~338 (2013)
- Russo A, "Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure : a review", Clin Ophthalmol, 2, pp.897~905 (2008)
- Schachtschabel U, "The mechanism of action of prostaglandins on uveoscleral outflow", Curr Opin Ophthalmol, 11, pp.112~115 (2000)
- Ooi YH, "and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells", Invest Ophthalmol Vis Sci, 50, pp.5259~5265 (2009)
- BenEzra D, "Collagens and non collagenous proteins in the human eye. I. Corneal stroma in vivo and keratocyte production in vitro", Curr Eye Res, 1, pp.101~110 (1981)
- Ehlers N, "Applanation tonometry and central corneal thickness", Acta Ophthalmol(Copenh), 53, pp.34~43 (1975)
- Goldmann H, "Applanation tonometry", Ophthalmologica, 134, pp.221~242 (1957)
- Alm A, "Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Scandinavian Latanoprost Study Group", Ophthalmology, 102, pp.1743~1752 (1995)
- Gordon MO, "The Ocular Hypertension Treatment Study : baseline factors that predict the onset of primary open-angle glaucoma", Arch Ophthalmol, 120, pp.714~720 (2002)
- Kim HJ, "Long-term effect of latanoprost on central corneal thickness in normal tension glaucoma", J Ocul Pharmacol Ther, 27, pp.73~76 (2011)
- Lee H, "Long-term effect of latanoprost on central corneal thickness in normal-tension glaucoma : five-year follow-up results", J Ocul Pharmacol Ther, 31, pp.152~155 (2015)
- Hatanaka M, "The effect of prostaglandin analogs and prostamide on central corneal thickness", J Ocul Pharmacol Ther, 25, pp.51~53 (2009)
- Greve EL, "Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: a review of short-term studies with three dose regimens of latanoprost treatment", Surv Ophthalmol, 41(Suppl 2), pp.S89~S92 (1997)
- McKibbin M, "The effect of once-daily latanoprost on intraocular pressure and pulsatile ocular blood flow in normal tension glaucoma", Eye (Lond), 13(Pt 1), pp.31~34 (1999)
- Sivak JM, "MMPs in the eye : emerging roles for matrix metalloproteinases in ocular physiology", Prog Retin Eye Res, 21, pp.1~14 (2002)
- Wang N, "Latanoprost and matrix metalloproteinase-1 in human choroid organ cultures", Curr Eye Res, 22, pp.198~207 (2001)
- Bergonzi C, "Evaluation of prostaglandin analogue effects on corneal keratocyte density using scanning laser confocal microscopy", J Glaucoma, 19, pp.617~621 (2010)
- Viswanathan D, "Longitudinal effect of topical antiglaucoma medications on central corneal thickness", Clin Exp Ophthalmol, 41, pp.348~354 (2013)
- Maruyama Y, "Effects of long-term topical prostaglandin therapy on central corneal thickness", J Ocul Pharmacol Ther, 30, pp.440~444 (2014)
- Stefan C, "Prostaglandin analogues and central corneal thickness", Oftalmologia, 51, pp.95~99 (2007)
- Zhong Y, "The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness", Cornea, 30, pp.861~864 (2011)
- 박명희, "프로스타글란딘 제제의 장기 점안이 각막두께에 미치는 영향", 대한안과학회지, 50(4), pp.565~571 (2009), 대한안과학회
- Maxey KM, "The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist", Surv Ophthalmol, 47(Suppl 1), pp.S34~S40 (2002)
- Fukano Y, "Metabolism and ocular tissue distribution of an antiglaucoma prostanoid, tafluprost, after ocular instillation to monkeys", J Ocul Pharmacol Ther, 27, pp.251~259 (2011)
- Doughty MJ, "Human corneal thickness and its impact on intraocular pressure measures : a review and meta-analysis approach", Surv Ophthalmol, 44, pp.367~408 (2000)
- Wu LL, "Central corneal thickness of normal tension glaucoma patients in Japan", Jpn J Ophthalmol, 44, pp.643~647 (2000)
- Singh RP, "Central corneal thickness, tonometry, and ocular dimensions in glaucoma and ocular hypertension", J Glaucoma, 10, pp.206~210 (2001)